A society for the immunology of radiation immunity.

The locked name

International Society for Radiation Immunity and Immuno-Modulation. There is no Oxford comma. Each element is deliberate. Radiation Immunity is the core frame, and the field of IJRM-SSS, the open-access journal of the CureRays Institute, in partnership with SIRiiM. Immunity names what radiation can confer — immunity conveyed by radiation, not immunity to it. Immunomodulation names the bidirectionality: the response can be heightened or blunted, and both are the Society’s business.

The acronym nests. The capitals carry the institutional frame; the two lowercase letters carry the mechanism, set inside it. Rendering the acronym from the international form follows the convention used by SIOP, SIU and SICOT.

How it began — the COVID-19 episode

In 2020, with critical-care capacity overwhelmed and no specific therapy, clinicians revived an idea from the pre-antibiotic era and irradiated the lungs of patients with severe COVID-19 pneumonia. The reasoning was not fanciful. Low-dose radiation had a documented anti-inflammatory effect, and the illness killing these patients was an inflammatory one. Trials opened worldwide, and a joint National Cancer Institute, NCRP and NIAID workshop convened to set a framework for conducting them — declining, pointedly, either to endorse or refute the approach.¹

The specific application did not work. A randomised, double-blind trial in ventilated patients found no difference in ventilator-free days and identical 28-day survival — 63.6% in both arms² — despite encouraging single-arm and matched-control results that preceded it. That is the honest record, and SIRiiM was not founded to dispute it.

What the failure revealed

The episode put radiation oncologists, radiobiologists, immunologists and intensivists in the same conversation — and the question that survived the trial was larger than the trial. The immunomodulatory effect of low-dose X-irradiation is not speculative. It has been characterised across leukocyte–endothelial adhesion, cytokine expression, apoptosis, and macrophage behaviour — and, strikingly, it is not linear. The effect peaks somewhere around 0.3–0.7 Gy and falls off on either side.³

A discontinuous dose–response is a signal that something specific is happening, not a smooth toxicological gradient. If immuno-modulatory radiation acts through identifiable immune pathways, then its plausible reach is not one virus. It is every disease in which those pathways are deranged — a set that is largely unmapped.

Why a society, rather than more single studies

Dozens of small, uncontrolled, differently designed studies produced encouraging results that a single properly randomised trial did not reproduce. The problem was not enthusiasm; it was the absence of shared protocols, agreed endpoints, dose conventions and a venue for publishing negative results.

SIRiiM was formed to supply that: concerted, standardised, sceptical study of radiation immunity and immunomodulation, so the next promising indication is tested properly the first time rather than re-learned the hard way.

The questions on the table

• Dose. Why the response peaks near 0.3–0.7 Gy, and whether that window is the same across tissues and diseases.
• Mechanism. Which immune pathways carry the effect, and whether it can be produced or blocked pharmacologically.
• Indication. Which inflammatory and immune-mediated conditions have a risk–benefit arithmetic that could justify irradiating a non-malignant disease at all.
• Risk. The radiogenic risk that any benign-disease indication must be weighed against, over the decades in which it would appear.
• Method. Shared protocols, endpoints and reporting standards — the thing whose absence made the COVID literature so hard to interpret.

Governance

SIRiiM guidance seats are VACANT while the founding society is newly organized. Officer and committee interest is Board-slate / internal — not an open seat-recruiting call. See Governance and Submit interest (internal).

References

1. Prasanna PG, Woloschak GE, DiCarlo AL, et al. Low-dose radiation therapy (LDRT) for COVID-19: benefits or risks? Radiat Res. 2020;194(5):452–464. doi:10.1667/RADE-20-00211.1
2. Papachristofilou A, Finazzi T, Blum A, et al. Low-dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study. Int J Radiat Oncol Biol Phys. 2021;110(5):1274–1282. doi:10.1016/j.ijrobp.2021.02.054
3. Rödel F, Frey B, Manda K, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol. 2012;2:120. doi:10.3389/fonc.2012.00120